Patents by Inventor Steven Hyun Seung LEE

Steven Hyun Seung LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION FOR TREATING DIABETIC RETINOPATHY, COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIANT CDNA
    Publication number: 20230024569
    Abstract: The present invention provides a pharmaceutical composition for treating diabetic retinopathy. According to the present invention, the pharmaceutical composition can treat diabetic retinopathy by means of a single administration and thus, compared to conventional treatment methods, which require intraocular injection on a monthly basis, can reduce pain and ocular damage and infections in patients and reduce treatment costs.
    Type: Application
    Filed: December 3, 2020
    Publication date: January 26, 2023
    Inventors: Steven Hyun Seung LEE, Kee Rang PARK, Young-lll LEE
  • COMPOSITION COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIENT CDNA FOR TREATMENT OF MACULAR DEGENERATION
    Publication number: 20200299356
    Abstract: The present invention relates to a pharmaceutical composition for treatment or prevention of macular degeneration and, more particularly, to a recombinant vector carrying a soluble VEGF receptor variant cDNA and a pharmaceutical composition comprising the same for treatment or prevention of macular degeneration. According to the present invention, age-related macular degeneration, which is a representative retinal disease causing blindness in adults, can be effectively treated and a prophylactic effect can be expected.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 24, 2020
    Inventors: Young-Ill Lee, Steven Hyun Seung Lee, Yeryang Kim, Jun-Sub Choi
  • Pharmaceutical composition containing mTOR inhibitor for treating macular degeneration
    Patent number: 10583150
    Abstract: The present invention relates to a pharmaceutical composition for treating macular degeneration, and more particularly to a pharmaceutical composition for treating macular degeneration, which comprises an inhibitor of mTOR gene expression. The pharmaceutical composition according to the present invention can effectively treat age-related macular degeneration, a representative retinal disease that causes blindness in adults.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 10, 2020
    Assignee: CuroGene Life Sciences Co., Ltd.
    Inventors: Young-Ill Lee, Steven Hyun Seung Lee, Tae Kwann Park
  • PHARMACEUTICAL COMPOSITION CONTAINING mTOR INHIBITOR FOR TREATING MACULAR DEGENERATION
    Publication number: 20190192551
    Abstract: The present invention relates to a pharmaceutical composition for treating macular degeneration, and more particularly to a pharmaceutical composition for treating macular degeneration, which comprises an inhibitor of mTOR gene expression. The pharmaceutical composition according to the present invention can effectively treat age-related macular degeneration, a representative retinal disease that causes blindness in adults.
    Type: Application
    Filed: March 17, 2017
    Publication date: June 27, 2019
    Inventors: Young-Ill LEE, Steven Hyun Seung LEE, Tae Kwann PARK